Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Decreases By 37.8%

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a significant decline in short interest in December. As of December 15th, there was short interest totalling 240,400 shares, a decline of 37.8% from the November 30th total of 386,500 shares. Based on an average daily volume of 3,380,000 shares, the short-interest ratio is presently 0.1 days. Currently, 3.1% of the company’s stock are short sold.

Virpax Pharmaceuticals Price Performance

Shares of VRPX opened at $0.34 on Friday. The firm has a 50-day moving average of $0.53 and a 200-day moving average of $0.75. Virpax Pharmaceuticals has a one year low of $0.29 and a one year high of $5.48.

Analyst Ratings Changes

Separately, Maxim Group reiterated a “hold” rating on shares of Virpax Pharmaceuticals in a report on Wednesday, October 9th.

Institutional Investors Weigh In On Virpax Pharmaceuticals

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new stake in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals as of its most recent SEC filing. Institutional investors own 32.23% of the company’s stock.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.